CliffBio
small molecule

ASMANEX HFA

MOMETASONE FUROATE

Loss of exclusivity—loss of exclusivity
CompanyOrganon →See this company's full patent-cliff portfolio

Drug detail

Brand nameASMANEX HFA
Active ingredientMOMETASONE FUROATE
Strength0.10MG/INH
Dosage formAEROSOL, METERED
RouteINHALATION
ModalitySmall molecule
FDA approvalApril 2014
Marketing statusRX

More from Organon

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ASMANEX HFA patent cliff — loss of exclusivity — | CliffBio